Archives: Speakers

Adam Barrows is a Clinical Trial Lead/Study Director for Bristol-Myers Squibb working in Oncology Clinical Development working on Immuno-Oncology agents in the Emerging Tumors team.  Adam started his career in clinical research working for ICON Clinical Research in data management and study start-up. Following his time at ICON, he worked in clinical pharmacology at Wyeth then trial operations at Merck.  Having spent the majority of his clinical research profession in clinical operations Adam has shifted his focus to strategic trial design and execution as part of the clinical development team at BMS.  As a passionate researcher, Adam has worked across multiple therapeutic areas in every phase of clinical research, from start-up to study closeout and brings his operational skills to the scientific execution of clinical trials.

Tim Phillips is the Managing Director of Tamarind Intelligence, publisher of leading business intelligence services ECigIntelligence, CBD-Intel and TobaccoIntelligence. These independent market data and regulatory tracking and analysis services for the vape, CBD and tobacco-alternatives industries provide market-leading insights into the sectors they cover for clients ranging from governments and academic institutions to multinational companies and professional service providers.

Tim Phillips is a UK-qualified attorney, having worked at the European Commission, international law firm Herbert Smith, media companies BSkyB and AOL, and Betfair, where he worked in various legal and government relations roles as the company went through its IPO. He was also a partner in a New York venture capital-funded start-up in the diamond sector. Tim holds a postgraduate diploma in legal practice from the University of Law, London and a masters degree in geology from Oxford University. He has run for Tamarind Intelligence for the past 6 years.

Jennifer is a senior life sciences executive with over two decades of experience turning breakthroughs into life-saving treatments. Jennifer has successfully contributed to the global approvals of seven novel treatments, generating $20B value creation.

Jennifer has business expertise in R&D leadership, strategic planning, business revitalization, global operations, and regulatory compliance.

Jennifer received a B.S. in biochemistry and an M.S. in clinical research and regulatory administration.

Have over 25 years of clinical research and clinical operations experience in several therapeutic areas including oncology working within academic, sponsor, and contract research organizations. Have managed early to late phase clinical trials with direct reports and working with vendors for specific study design needs. Have assessed data collection/verification through final analyses ultimately used in progress, final study reports, and regulatory agency filings. Have worked with key opinion leaders and others in preparing clinical data for peer-reviewed publications and developed educational and other materials to focus on study site participation and recruitment strategy..  Privileged to have worked with teams to complete,

• Six (6) pharmaceutical trials which followed the IND path and were approved via an NDA.
• Three (3) IDE trials; ultimately approved via a PMA path.
• Three (3) trials which followed a 510(k) path with successful equivalency performance